Biomedical
Antibodies that disrupt the PD-L1•PD-1, checkpoint inhibitors, are a direct approach to immunotherapy. However, several indirect, more subtle, strategies are emerging to control levels of PD-L1 expression on tumors, and this Highlights discusses a few.